Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial by Nicolau, Jose C. et al.
  
 
 
Nicolau, J. C. et al. (2019) Does prior coronary angioplasty affect outcomes of 
surgical coronary revascularization? Insights from the STICH trial. International 
Journal of Cardiology, 291, pp. 36-41. (doi:10.1016/j.ijcard.2019.03.029)  
 
There may be differences between this version and the published version. You are 
advised to consult the publisher’s version if you wish to cite from it. 
 
 
 
http://eprints.gla.ac.uk/182871/ 
      
 
 
 
 
 
 
Deposited on: 26 March 2019 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Accepted Manuscript
Does prior coronary angioplasty affect outcomes of surgical
coronary revascularization? Insights from the STICH trial
Jose C. Nicolau, Susanna R. Stevens, Hussein R. Al-Khalidi,
Fabio B. Jatene, Remo H.M. Furtado, Luis A.O. Dallan, Luiz A.F.
Lisboa, Patrice Desvigne-Nickens, Haissam Haddad, E. Marc
Jolicoeur, Mark C. Petrie, Torsten Doenst, Robert E. Michler, E.
Magnus Ohman, Jyotsna Maddury, Imtiaz Ali, Marek A. Deja,
Jean L. Rouleau, Eric J. Velazquez, James A. Hill
PII: S0167-5273(19)30541-8
DOI: https://doi.org/10.1016/j.ijcard.2019.03.029
Reference: IJCA 27529
To appear in: International Journal of Cardiology
Received date: 28 January 2019
Revised date: 25 February 2019
Accepted date: 14 March 2019
Please cite this article as: J.C. Nicolau, S.R. Stevens, H.R. Al-Khalidi, et al., Does prior
coronary angioplasty affect outcomes of surgical coronary revascularization? Insights
from the STICH trial, International Journal of Cardiology, https://doi.org/10.1016/
j.ijcard.2019.03.029
This is a PDF file of an unedited manuscript that has been accepted for publication. As
a service to our customers we are providing this early version of the manuscript. The
manuscript will undergo copyediting, typesetting, and review of the resulting proof before
it is published in its final form. Please note that during the production process errors may
be discovered which could affect the content, and all legal disclaimers that apply to the
journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
                Page 1   
Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? 
Insights from the STICH trial 
 
 
Jose C. Nicolau, MD,
a
 Susanna R. Stevens, MS,
b
 Hussein R. Al-Khalidi, PhD,
b
 Fabio B. Jatene, 
MD,
a
 Remo H. M. Furtado, MD,
a
  Luis A. O. Dallan, MD,
a
 Luiz A. F. Lisboa, MD,
a
  Patrice 
Desvigne-Nickens, MD,
c
  Haissam Haddad, MD,
d
  E. Marc Jolicoeur, MD,
e
  Mark C. Petrie, 
MBChB,
f
  Torsten Doenst, MD, PhD,
g
  Robert E. Michler, MD,
h
  E. Magnus Ohman, MD,
b
  
Jyotsna Maddury, MD,
i
  Imtiaz Ali, MD,
j
  Marek A. Deja, MD, PhD,
k
  Jean L. Rouleau, MD,
e
  
Eric J. Velazquez, MD,
l
  James A. Hill, MD
m
 
 
a
Instituto do Coracao (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, 
Universidade de Sao Paulo, Sao Paulo, SP, Brazil 
 
b
Duke Clinical Research Institute and Department of Biostatistics and Bioinformatics, Duke 
University School of Medicine, Durham, NC, USA 
c
Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National 
Institutes of Health, Bethesda, MD, USA 
d
Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada 
e
Montreal Heart Institute, Université de Montréal, Quebec, Canada 
f
BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom 
g
Department of Cardiothoracic Surgery, University of Jena, Jena, Germany 
h
Department of Cardiothoracic Surgery, Montefiore Medical Center/Albert Einstein College of 
Medicine, New York, NY, USA 
i
Department of Cardiology, Nizams Institute of Medical Sciences, Hyderabad, India 
i
Libin Cardiovascular Institute of Alberta, University of Calgary, Foothills Medical Centre, 
Calgary, Alberta, Canada 
k
Department of Cardiac Surgery, Medical University of Silesia, Katowice, Poland 
l
Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA 
m
Department of Medicine, University of Florida, Gainesville, FL, USA 
 
Total Word Count:  4,807 (from Title page through Tables)    
 
 
 
Corresponding Author:  
Jose C. Nicolau 
Aureliano Coutinho 355; apt. 1401; São Paulo, Brazil, 01224-020 
 Telephone: +55-11-26615058; Fax: +55-11-30883809 
 E-mail: jose.nicolau@incor.usp.br 
      
 
 
 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
                Page 2   
ABSTRACT 
 
Background The STICH trial showed superiority of coronary artery bypass plus medical 
treatment (CABG) over medical treatment alone (MED) in patients with left ventricular ejection 
fraction (LVEF) 35%. In previous publications, percutaneous coronary intervention (PCI) prior 
to CABG was associated with worse prognosis. 
Objectives The main purpose of this study was to analyse if prior PCI influenced outcomes in 
STICH. 
Methods and Results: Patients in the STICH trial (n=1212), followed for a median time of 9.8 
years, were included in the present analyses. In the total population, 156 had a prior PCI (74 and 
82, respectively, in the MED and CABG groups). In those with vs. without prior PCI, the 
adjusted hazard-ratios (aHRs) were 0.92 (95% CI=0.74-1.15) for all-cause mortality, 0.85 (95% 
CI=0.64-1.11) for CV mortality, and 1.43 (95% CI=1.15-1.77) for CV hospitalization. In the 
group randomized to CABG without prior PCI, the aHRs were 0.82 (95% CI=0.70-0.95) for all-
cause mortality, 0.75 (95% CI=0.62-0.90) for CV mortality and 0.67 (95% CI=0.56-0.80) for CV 
hospitalization. In the group randomized to CABG with prior PCI, the aHRs were 0.76 (95% 
CI=0.50-1.15) for all-cause mortality, 0.81 (95% CI=0.49-1.36) for CV mortality and 0.61 (95% 
CI=0.41-0.90) for CV hospitalization. There was no evidence of interaction between randomized 
treatment and prior PCI for any endpoint (all adjusted p>0.05).   
Conclusion In the STICH trial, prior PCI did not affect the outcomes of patients whether they 
were treated medically or surgically, and the superiority of CABG over MED remained 
unchanged regardless of prior PCI. 
  
 
Clinical Trial Registration:  Clinicaltrials.gov; Identifier: NCT00023595 
 
 
Key Words: coronary artery bypass surgery, heart failure, left ventricular dysfunction, 
percutaneous coronary intervention 
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INTRODUCTION  
Coronary artery bypass graft (CABG) surgery has been established as the standard of 
care for patients with multi-vessel coronary artery disease (CAD) and left ventricular (LV) 
dysfunction (1, 2). Although this was first suggested by subgroup analyses from older 
randomized trials, in subgroup analyses with small numbers of patients (3, 4),
 
more recently the 
STICH trial definitely demonstrated a significant long-term mortality reduction favoring CABG 
versus medical treatment alone (MED) specifically in patients with LVEF 35% (5, 6).  
Whether the same benefit could be conferred by percutaneous coronary intervention 
(PCI) is a matter of debate (7-10), with a meta-analysis demonstrating superiority of PCI and 
CABG over MED, with survival advantage favoring CABG in comparison with PCI (11). 
In previous reports, prior PCI has been associated with worse short-term outcomes after 
CABG (12-14) and to increased long-term postoperative mortality (15). However, this claim has 
been disputed by recent reports.  Ueki, et al., analyzing more than 48,000 individuals undergoing 
CABG (12,437 with prior PCI), found the same operative mortality (1.2%) in the groups with or 
without prior PCI. Mariscalco, et al. found an odds-ratio of 0.90 (with vs. without prior PCI) for 
in-hospital mortality (P=0.81), raising the question whether there could be any influence of 
selection bias due to inclusion of prior PCI in an urgent setting in the previous studies (16,17). 
However, none of those reports specifically addressed the high-risk population with severe LV 
dysfunction.   Therefore, we sought to investigate in the STICH trial (which randomized patients 
with LVEF ≤35% to CABG plus MED or MED alone) whether prior PCI influences the benefit 
of CABG compared to MED.   
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METHODS 
Population 
The STICH trial was a prospective, multicenter, randomized trial sponsored by the 
National Heart, Lung and Blood Institute that enrolled 1212 individuals from 22 countries and 99 
sites.  STICH trial hypothesis 1 enrollment criteria, as well as the main results, have been 
published previously (18, 5).
 
Briefly, patients with multi-vessel CAD and LVEF 35% who were 
deemed suitable for surgical revascularization were randomized to optimal medical treatment 
with or without CABG and followed-up for a median of 9.8 years after a protocol amendment to 
the initial planned 5-year follow-up  (6). The main exclusion criteria were presence of a left main 
coronary stenosis of 50% or more of the artery diameter, Canadian Cardiovascular Society class 
III or IV angina on MED, plan for PCI and history of acute myocardial infarction within 30 days. 
STICH hypothesis 1 investigated whether CABG would be superior to MED in terms of the 
main primary endpoint of all-cause mortality, as well as the secondary endpoints of 
cardiovascular mortality, the composite of all-cause death or hospitalization due to 
cardiovascular (CV) causes, and CV hospitalization.  
For the purposes of the present study, the database from the trial was retrospectively 
analyzed regarding whether patients had undergone PCI prior to enrollment. Data was not 
available regarding details of the PCI procedure including vessels involved, timing of the 
procedures in relation to study entry, use and type of stents or clinical circumstances (eg. acute 
coronary syndromes or elective, etc). 
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The authors reviewed the data, participated in the analyses and wrote the manuscript,and 
assume responsibility for the completeness and accuracy of the data and the analyses and for the 
fidelity of the study to the trial protocol. 
 
Statistical analyses 
Baseline patient characteristics are summarized for those with and without prior PCI.  
Unless otherwise noted, continuous variables are depicted as medians (25
th
, 75
th
 percentiles) and 
prior PCI groups compared with Wilcoxon rank-sum tests. Categorical variables are summarized 
as counts (percentages) and groups were compared with Pearson’s chi-square or Fisher’s exact 
tests as appropriate.  
For the comparison of outcomes (all-cause mortality, CV mortality, CV hospitalization, 
and the composite of all-cause death or CV hospitalization) for patients with and without prior 
PCI, Cox proportional hazards models were fit.  Results are presented as number of events, 
Kaplan-Meier rate at 10 years, hazard ratio with 95% confidence interval (CI), and p-value. 
Unadjusted models were adjusted for variables that were associated with any outcome at 0.05 
level of significance. Adjusted models were developed from Cox models using backward 
elimination method. The following baseline variables were selected at the 0.05 level of 
significance: age, sex, region, creatinine clearance, randomized treatment, prior CABG, number 
and location of diseased vessels, heart rate, NYHA class III or IV, atrial fibrillation, moderate or 
severe mitral regurgitation, end systolic volume index, diabetes, stroke, current smoking, chronic 
renal insufficiency, depression, and ACE/ARB use.  There were a few missing values in this 
study and a multiple imputation technique was used.  
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Cox proportional hazards models including treatment, prior PCI, and the treatment-by-
prior PCI history interaction were used to test for a differential treatment effect (CABG versus 
MED) in patients with or without prior PCI.  Adjusted and unadjusted models were fit for 
treatment as randomized and as received. Kaplan-Meier plots have been produced for prior PCI 
vs. no prior PCI groups that were stratified by treatment. Unadjusted hazard ratios and 95% 
confidence intervals for treatment with CABG are provided for those with and without prior PCI 
along with the interaction p-value.  
As a sensitivity analysis, the unadjusted models for the association between prior PCI and 
outcomes were adjusted for propensity score.  The propensity scores were calculated using a 
logistic regression model including clinically important variables and variables associated with 
having prior PCI in current data.  Variables included sex, age, race, previous CABG, previous 
internal cardiac defibrillator, diabetes, NYHA class, weight, creatinine, systolic blood pressure, 
angina, moderate or severe mitral regurgitation, smoking, hypercholesterolemia, prior 
myocardial infarction, ejection fraction, ACE/ARB, statins, potassium sparing diuretic, number 
of diseased vessels and disease of proximal left anterior descending. We checked for 
confounding and the departure from the linearity assumption among covariates before adjusting 
the model to get the propensity scores.    
All statistical analyses were two-sided and a p-value <0.05 was considered as statistically 
significant. SAS version 9.4 (SAS Institute, Inc., Cary, NC) was used for all statistical analyses. 
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RESULTS 
Of the 1212 patients enrolled (602 randomized to MED and 610 to CABG), 156 (12.9%) 
had a prior PCI (74 in the MED group and 82 in the CABG group).  Patients with prior PCI more 
frequently had a history of hyperlipidemia, myocardial infarction, and moderate or severe mitral 
regurgitation.  They had greater severity of angina, more frequently implanted with a 
cardioverter defibrillator, and were less likely to have disease in the left anterior descending 
artery.  Clinical characteristics are shown by PCI history in Table 1 with groups further grouped 
by randomized treatment in Supplemental Table 1. 
 
Relationship between prior PCI and outcomes  
As can be seen in Table 2, Kaplan-Meier rates at 10 years were respectively 60.2% and 
64.3% for patients with or without previous PCI for all-cause mortality (adjusted HR=0.92, 95% 
CI, 0.74-1.15), and 44.5% compared with 51.0% for CV mortality, respectively (adjusted 
HR=0.85, 95% CI, 0.64-1.11). Conversely, all-cause mortality or CV hospitalization (adjusted 
HR=1.19, 95% CI 0.99-1.44) and CV hospitalization alone (adjusted HR 1.43, 95% CI, 1.15-
1.77) were greater in patients with prior PCI. There were no significant differences regarding the 
main causes of hospitalization between patients with or without prior PCI: heart failure (27% vs. 
29%, respectively), unstable angina (15% vs. 11%), arrhythmias (11% vs. 10%) or infection (9% 
vs. 8%). In the sensitivity analysis adjusted for the propensity to have prior PCI, similar results 
for mortality were observed for all-cause and CV mortalities, but the hazard ratio of CV 
hospitalization in patients with prior PCI was no longer significant (adjusted HR=1.20 (95% CI, 
0.95-1.50) (Supplement Table 2). 
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Influence of prior PCI on outcomes in the STICH trial 
By intention to treat, the reduced risk of all-cause mortality, CV mortality, CV 
hospitalization, and the all-cause mortality or CV hospitalization composite that was observed 
with CABG and MED in comparison with MED alone overall in the trial, was not dependent on 
whether patients had PCI prior to randomization. Interaction p-values were not significant for 
any endpoint with or without adjustment (Figure 1 and Supplemental Figure 1). By treatment 
received, as can be seen in Table 3, the results were similar to the previous ones, with no 
significant interaction for any of the analyzed endpoints. 
 
 
 
DISCUSSION 
In this high-risk population comprised of patients with LVEF 35%, our results showed 
that prior PCI was not associated with an increased risk of all-cause and CV mortality. 
Moreover, in the STICH trial CABG remained superior to MED whether patients were treated 
with or without PCI prior to enrollment. 
The prevalence of prior PCI has been increasing steadily in patients undergoing CABG 
(19) (20). The prevalence in the present experience (12.9%) is similar to the median of 12.7% 
reported by Mehta, et al. in a meta-analysis that included more than 34,000 patients (about 10% 
with heart failure) (19), and similar to the incidence found by Nauffal, et al. in patients with 
triple-vessel disease and diabetes (12.8%) (21), and lower than the incidences described by 
Niclauss (24%) (20) and O’Neill (19%) (22). These differences may be related to the time period 
reported in the respective studies or some other factor. 
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Relationship between prior PCI and outcomes in patients submitted to CABG  
Contrary to our results, although not unanimously, previous publications, mainly in 
patients with preserved LV function, have suggested that the presence of prior PCI is associated 
with worse short- and long-term prognosis of patients who underwent CABG (12-15), which 
could be influenced by a decrease in the number of grafts utilized in patients with prior PCI (12). 
In the present study, the number of grafts was similar in patients with or without prior PCI in 
accordance to Thielmann, et al. findings (13). Songur, et al., analyzing patency rates in patients 
with or without prior PCI, found significantly higher graft patency rates for the group without 
prior PCI in left anterior descending, circumflex, and right coronary arteries at a mean time of 60 
months (23), which could be related to competitive flow, as suggested by the results of the 
recently presented IMPAG trial (24). Conversely, the EuroSCORE and the STS risk model have 
been found to be inaccurate in predicting outcomes after CABG in patients with prior PCI, with 
an area under the curve (EuroSCORE) for 30-day mortality of 0.875 for patients without prior 
PCI, and only 0.552 for patients with prior PCI (25).  
In our patients assigned to CABG, we found a non-significant decrease in all-cause and 
CV mortality rates for those with prior PCI (HR=0.85 and 0.84, respectively) as compared with 
those without prior PCI, a finding similar to that of Luthra et al., who described higher survival 
rates for patients having CABG with prior PCI and LVEF<30%, but not for those with LVEF 
>30% (26). Finally, for CV hospitalization, we observed a higher rate (statistically significant in 
the model adjusted by baseline variables but not significant in the model adjusted for propensity 
for prior PCI) during the follow-up in patients with prior PCI. Additionally, unstable angina 
requiring hospitalization was similar between the groups, contrary to the findings of Chocron, et 
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al. who found a higher incidence in patients with prior PCI, but in a population with LVEF >39% 
(27). 
CABG vs. MED: the influence of prior PCI 
 Before the present analysis, no publications specifically assessed the role of prior PCI in 
patients with LVEF <35% submitted to CABG or MED. In a meta-analysis with 21 studies and 
>16,000 patients with LVEF <40%, Wolff, et al. found a significant superiority of CABG over 
MED (HR=0.66, P<0.001) (11).  However, the important hypothesis that prior PCI could 
influence CABG results was not addressed in that publication. In this context, our results are 
reassuring, showing that CABG is superior to MED in patients with or without previous PCI, 
with consistent results for both as randomized and as treated analyses.  
Study limitations 
There are several limitations to the current study. First, although similar to other reports, 
the analysis is post-hoc with a relatively small number of patients. Second, we collected no 
detailed information specific to the intervention performed. The modern practice of PCI is 
complex and how data from the current study relates to that practice is unknown and may have 
influenced the results (13, 21). However, this is the only report we are aware of limited to a 
population with LV dysfunction maintained on optimal medical therapy that analyzes the impact 
of prior PCI in patients undergoing CABG or maintained on MED alone. Finally, while our 
analysis is the largest so far to specifically assess the association of prior PCI and outcomes in 
patients with LV dysfunction treated with CABG, we cannot exclude that a lack of statistical 
power might have been an issue.  
 
Conclusion  
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 In the STICH population of patients with ischemic heart disease and LVEF  35%, 
patients with prior PCI did not have a worse prognosis compared to those who did not. 
Moreover, the previously demonstrated benefit of CABG plus optimal medical therapy over 
MED alone was maintained regardless of whether patients had prior PCI. This report supports 
the idea that prior PCI should not be a factor in whether to offer CABG to patients with LV 
dysfunction. 
 
 
Acknowledgements 
The authors thank Carlos José Dornas Gonçalves, MD for his suggestions on the analyses and 
Vanessa Moore for her editorial assistance with this manuscript. 
 
Sources of Funding   
This work was supported by the National Institutes of Health, National Heart, Lung, and Blood 
Institute grants U01 HL069015, U01 HL069013, and R01 HL105853. This work is solely the 
responsibility of the authors and does not necessarily represent the official views of the National 
Heart, Lung, and Blood Institute or National Institutes of Health. 
 
 
Relationship with Industry and Other Entities: Dr. Nicolau reports research grants (modest) 
from Amgen, Bayer, Bristol-Myers Squibb, DalCor, Janssen, Sanofi, AstraZeneca, Boehringer 
Ingelheim, Novartis, and Pfizer; and consulting/advisory board fees (modest) from Sanofi, 
Amgen, Vifor, and Servier, outside the submitted work. Dr. Furtado reports honoraria from 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
                Page 12   
AstraZeneca (modest) and grants (modest) from AstraZeneca, DalCor, Boehringer, 
Pfizer, Jansen and Sanofi, outside the submitted work. Dr. Velazquez reports research grants 
(significant) with Novartis, Amgen, National Heart, Lung, and Blood Institute, Pfizer and 
Alnylam and consultant/advisory board agreements (modest) with Novartis, Amgen, and Philips. 
Dr. Jolicoeur reports research grants (significant) from AstraZeneca, Boston Scientifics, and 
Philips, and consultant/advisory board agreements (modest) with Servier. All other co-authors 
have nothing to disclose.  
REFERENCES 
 
1. Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk 
V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, 
Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini 
GG, Taggart DP, Torracca L, Valgimigli , Wijns W, Witkowski A.  2014 ESC/EACTS 
Guidelines on myocardial revascularization: The Task Force on Myocardial 
Revascularization of the European Society of Cardiology (ESC) and the European 
Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution 
of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur 
Heart J 2014;35:2541-619. 
2. Patel MR, Calhoon JH, Dehmer GJ, Grantham JA, Maddox TM, Maron DJ, Smith PK. 
ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for 
Coronary Revascularization in Patients With Stable Ischemic Heart Disease: A Report of 
the American College of Cardiology Appropriate Use Criteria Task Force, American 
Association for Thoracic Surgery, American Heart Association, American Society of 
Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
                Page 13   
Angiography and Interventions, Society of Cardiovascular Computed Tomography, and 
Society of Thoracic Surgeons. J Am Coll Cardiol 2017;69:2212-41. 
3. Veterans ACABSCSG. Eleven-year survival in the Veterans Administration randomized 
trial of coronary bypass surgery for stable angina. N Engl J Med 1984;311:1333-9. 
4. Passamani E, Davis KB, Gillespie MJ, Killip T. A randomized trial of coronary artery 
bypass surgery. Survival of patients with a low ejection fraction. N Engl J Med 
1985;312:1665-71. 
5. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, 
Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie MC, 
O'Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, Rouleau JL; 
STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular 
dysfunction. N Engl J Med 2011;364:1607-16.  
6. Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, Michler RE, Bonow 
RO, Doenst T, Petrie MC, Oh JK, She L, Moore VL, Desvigne-Nickens P, Sopko G, 
Rouleau JL; STICHES Investigators.Coronary-Artery Bypass Surgery in Patients with 
Ischemic Cardiomyopathy. N Engl J Med 2016;374:1511-20. 
7. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic 
therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. 
Lancet 2003;361:13-20. 
8. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Ståhle E, 
Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr 
FW; SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery 
bypass grafting for severe coronary artery disease. N Engl J Med 2009;360:961-72. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
                Page 14   
9. Bangalore S, Guo Y, Samadashvili Z, Blecker S, Hannan EL. Revascularization in Patients 
With Multivessel Coronary Artery Disease and Severe Left Ventricular Systolic 
Dysfunction: Everolimus-Eluting Stents Versus Coronary Artery Bypass Graft Surgery. 
Circulation 2016;133:2132-40. 
10. Kang SH, Lee CW, Baek S, Lee PH, Ahn JM, Park DW, Kang SJ, Lee SW, Kim YH, Park 
SW, Park SJ. Comparison of Outcomes of Coronary Artery Bypass Grafting Versus Drug-
Eluting Stent Implantation in Patients With Severe Left Ventricular Dysfunction. Am J 
Cardiol 2017;120:69-74. 
11. Wolff G, Dimitroulis D, Andreotti F, Kołodziejczak M, Jung C, Scicchitano P, Devito F, 
Zito A, Occhipinti M, Castiglioni B, Calveri G, Maisano F, Ciccone MM, De Servi S, 
Navarese EP. Survival Benefits of Invasive Versus Conservative Strategies in Heart Failure 
in Patients With Reduced Ejection Fraction and Coronary Artery Disease: A Meta-
Analysis. Circ Heart Fail 2017;10:e003255. 
12. Hassan A, Buth KJ, Baskett RJ, Ali IS, Maitland A, Sullivan JA, Ghali WA, Hirsch GM. 
The association between prior percutaneous coronary intervention and short-term outcomes 
after coronary artery bypass grafting. Am Heart J 2005;150:1026-31.  
13. Thielmann M, Leyh R, Massoudy P, Neuhäuser M, Aleksic I, Kamler M, Herold U, 
Piotrowski J, Jakob H. Prognostic significance of multiple previous percutaneous coronary 
interventions in patients undergoing elective coronary artery bypass surgery. Circulation 
2006;114:I441-7. 
14. Lisboa LA, Mejia OA, Dallan LA, Moreira LF, Puig LB, Jatene FB, Stolf NA. Previous 
percutaneous coronary intervention as risk factor for coronary artery bypass grafting. Arq 
Bras Cardiol 2012;99:586-95.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
                Page 15   
15. Mannacio V, Di Tommaso L, De Amicis V, Lucchetti V, Pepino P, Musumeci F, Vosa C. 
Previous percutaneous coronary interventions increase mortality and morbidity after 
coronary surgery. Ann Thorac Surg 2012;93:1956-62.  
16. Ueki C, Miyata H, Motomura N, Sakaguchi G, Akimoto T, Takamoto S. Previous 
Percutaneous Coronary Intervention Does Not Increase Adverse Events After Coronary 
Artery Bypass Surgery. Ann Thorac Surg 2017;104:56-61. 
17. Mariscalco G, Rosato S, Serraino GF, Maselli D, Dalén M, Airaksinen JKE, Reichart D, 
Zanobini M, Onorati F, De Feo M, Gherli R, Santarpino G, Rubino AS, Gatti G, Nicolini F, 
Santini F, Perrotti A, Bruno VD, Ruggieri VG, Biancari F. Prior Percutaneous Coronary 
Intervention and Mortality in Patients Undergoing Surgical Myocardial Revascularization: 
Results From the E-CABG (European Multicenter Study on Coronary Artery Bypass 
Grafting) With a Systematic Review and Meta-Analysis. Circ Cardiovasc Interv 
2018;11:e005650. 
18. Velazquez EJ, Lee KL, O'Connor CM, Oh JK, Bonow RO, Pohost GM, Feldman AM, 
Mark DB, Panza JA, Sopko G, Rouleau JL, Jones RH; STICH Investigators. The rationale 
and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. J Thorac 
Cardiovasc Surg 2007;134:1540-7.  
19. Mehta GS, LaPar DJ, Bhamidipati CM, Kern JA, Kron IL, Upchurch GR Jr, Ailawadi G. 
Previous percutaneous coronary intervention increases morbidity after coronary artery 
bypass grafting. Surgery 2012;152:5-11.  
20. Niclauss L, Colombier S, Prêtre R. Percutaneous coronary interventions prior to coronary 
artery bypass surgery. J Card Surg 2015;30:313-8. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
                Page 16   
21. Nauffal V, Schwann TA, Yammine MB, El-Hage-Sleiman AK, El Zein MH, Kabour A, 
Engoren MC, Habib RH. Impact of prior intracoronary stenting on late outcomes of 
coronary artery bypass surgery in diabetics with triple-vessel disease. J Thorac Cardiovasc 
Surg 2015;149:1302-9.  
22. O'Neal WT, Efird JT, Anderson CA, Kindell LC, O'Neal JB, Bruce Ferguson T, Randolph 
Chitwood W, Kypson AP. The impact of prior percutaneous coronary intervention on long-
term survival after coronary artery bypass grafting. Heart Lung Circ 2013; 22: 940-5. 
23. Songur MÇ, Özyalçin S, Özen A, Şimşek E, Kervan Ü, Taşoğlu İ, Kaplan S, Köse K, Ulus 
AT. Does really previous stenting affect graft patency following CABG? A 5-year follow-
up: The effect of PCI on graft survival. Heart Vessels 2016;31:457-64. 
24.  Freemantle N, Milojevic M, Lim S, Fremes S, Pagano D. 32nd EACTS Annual Meeting 
clinical trials update: ART, IMPAG, MITRA-FR and COAPT. Eur J Cardiothorac Surg 
2018; doi:10.1093/ejcts/ezy396 
25. Bonaros N, Vill D, Wiedemann D, Fischler K, Friedrich G, Pachinger O, Grimm M, 
Schachner T. Major risk stratification models do not predict perioperative outcome after 
coronary artery bypass grafting in patients with previous percutaneous intervention. Eur J 
Cardiothorac Surg 2011;39:e164-9.   
26. Luthra S, Leiva Juárez MM, Senanayake E, Luckraz H, Billing JS, Cotton J, Norell MS. 
Percutaneous intervention before coronary artery bypass surgery does not unfavorably 
impact survival: A single-center propensity-matched analysis. Ann Thorac Surg 
2016;102:1911-8. 
27. Chocron S, Baillot R, Rouleau JL, Warnica WJ, Block P, Johnstone D, Myers MG, Calciu 
CD, Nozza A, Martineau P, van Gilst WH; IMAGINE Investigators. Impact of previous 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
                Page 17   
percutaneous transluminal coronary angioplasty and/or stenting revascularization on 
outcomes after surgical revascularization: insights from the imagine study.  Eur Heart J 
2008;29:673-9.   
 
 
 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
                Page 18   
Figure Legends 
 
 
Figure 1. Randomized treatment effects by history of PCI 
* Models are adjusted for baseline age, sex, region, creatinine clearance, prior CABG, diseased 
vessels, heart rate, NYHA class, AF, MR, ESVI, diabetes, stroke, current smoking, chronic renal 
insufficiency, depression, and ACE/ARB use.  CV=cardiovascular; ACM=all-cause mortality 
 
Supplemental Figure 1. Coronary artery bypass versus medical treatment only. Kaplan-Meier 
rates of all-cause mortality (A), cardiovascular mortality (B), all-cause mortality of 
cardiovascular hospitalization (C) and cardiovascular hospitalization (D).  
 
Dashed lines represent those randomized to medical therapy and solid lines those randomized to 
CABG plus medical therapy. 
 
Table 1. Baseline patient characteristics by prior PCI 
 
All patients  
(N=1212) 
No prior PCI  
(N=1056) 
Prior PCI  
(N=156) p-value 
Age (years) 60 (54, 67) 60 (54, 67) 59 (54, 67) 0.518 
Female sex 148 (12.2%) 123 (11.6%) 25 (16.0%) 0.119 
Race    <0.001 
White 827 (68.2%) 698 (66.1%) 129 (82.7%)  
Black 31 (2.6%) 26 (2.5%) 5 (3.2%)  
Asian 209 (17.2%) 193 (18.3%) 16 (10.3%)  
Other 145 (12.0%) 139 (13.2%) 6 (3.8%)  
Body mass index (kg/m
2
) 26.8 (24.0, 29.8) 26.7 (23.9, 29.7) 27.8 (24.4, 30.2) 0.059 
Systolic blood pressure (mmHg) 120 (110, 130) 120 (110, 130) 120 (108, 130) 0.019 
Diastolic blood pressure (mmHg) 78 (70, 80) 80 (70, 80) 75 (68, 80) 0.072 
Heart rate (bpm) 74 (66, 82) 74 (66, 81) 72 (66, 84) 0.828 
Hemoglobin (g/dL) 13.9 (12.7, 14.9) 13.9 (12.7, 14.9) 13.9 (12.7, 14.7) 0.213 
Cockcroft-Gault creatinine clearance (mg/dL) 76.5 (60.5, 95.9) 76.1 (60.4, 94.8) 80.1 (61.7, 104.8) 0.119 
LVEF 28 (22, 34) 28 (23, 34) 26 (21, 33) 0.197 
ESVI (mL/m
2
) 78.0 (60.9, 99.1) 77.8 (60.6, 99.1) 80.4 (61.6, 99.0) 0.495 
Diabetes 478 (39.4%) 415 (39.3%) 63 (40.4%) 0.796 
Hyperlipidemia 730 (60.3%) 623 (59.1%) 107 (68.6%) 0.024 
Hypertension 728 (60.1%) 628 (59.5%) 100 (64.1%) 0.270 
Peripheral vascular disease 184 (15.2%) 166 (15.7%) 18 (11.5%) 0.174 
Myocardial infarction 934 (77.1%) 799 (75.7%) 135 (86.5%) 0.003 
Stroke 92 (7.6%) 80 (7.6%) 12 (7.7%) 0.959 
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All patients  
(N=1212) 
No prior PCI  
(N=1056) 
Prior PCI  
(N=156) p-value 
Moderate or severe mitral regurgitation 220 (18.2%) 179 (17.0%) 41 (26.3%) 0.005 
Prior ICD 29 (2.4%) 20 (1.9%) 9 (5.8%) 0.008 
Prior CABG 36 (3.0%) 29 (2.7%) 7 (4.5%) 0.212 
Atrial fibrillation or flutter 153 (12.6%) 131 (12.4%) 22 (14.1%) 0.551 
Current smoking 252 (20.8%) 219 (20.8%) 33 (21.2%) 0.910 
CCS angina class    0.006 
0 442 (36.5%) 383 (36.3%) 59 (37.8%)  
I 187 (15.4%) 167 (15.8%) 20 (12.8%)  
II 525 (43.3%) 464 (43.9%) 61 (39.1%)  
III 48 (4.0%) 36 (3.4%) 12 (7.7%)  
IV 10 (0.8%) 6 (0.6%) 4 (2.6%)  
NYHA class    0.356 
I 139 (11.5%) 121 (11.5%) 18 (11.5%)  
II 626 (51.7%) 547 (51.8%) 79 (50.6%)  
III 412 (34.0%) 361 (34.2%) 51 (32.7%)  
IV 35 (2.9%) 27 (2.6%) 8 (5.1%)  
Baseline medications     
ACE inhibitor or ARB 1085 (89.5%) 938 (88.8%) 147 (94.2%) 0.040 
Beta blocker 1036 (85.5%) 898 (85.0%) 138 (88.5%) 0.257 
Aspirin 1002 (82.7%) 874 (82.8%) 128 (82.1%) 0.826 
Clopidogrel 208 (17.2%) 176 (16.7%) 32 (20.5%) 0.234 
Antiarrhythmic (including amiodarone) 128 (10.6%) 112 (10.6%) 16 (10.3%) 0.894 
Digoxin 245 (20.2%) 215 (20.4%) 30 (19.2%) 0.743 
Insulin 197 (16.3%) 168 (15.9%) 29 (18.6%) 0.397 
Oral diabetic agent 286 (23.6%) 252 (23.9%) 34 (21.8%) 0.570 
Nitrate 646 (53.3%) 562 (53.2%) 84 (54.2%) 0.820 
Statin 983 (81.1%) 847 (80.2%) 136 (87.2%) 0.038 
Warfarin 127 (10.5%) 111 (10.5%) 16 (10.3%) 0.923 
Diuretic-loop thiazide 791 (65.3%) 700 (66.3%) 91 (58.7%) 0.064 
Diuretic-potassium sparing 556 (45.9%) 473 (44.8%) 83 (53.2%) 0.049 
Coronary anatomy     
Number of diseased vessels (75%)    0.046 
0 25 (2.1%) 19 (1.8%) 6 (3.9%)  
1 282 (23.3%) 243 (23.0%) 39 (25.2%)  
2 462 (38.2%) 395 (37.4%) 67 (43.2%)  
3 442 (36.5%) 399 (37.8%) 43 (27.7%)  
Left main stenosis ≥ 50% 32 (2.6%) 28 (2.7%) 4 (2.6%) 1.000 
Proximal LAD stenosis ≥ 75% 826 (68.2%) 734 (69.5%) 92 (59.4%) 0.011 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
                Page 20   
 
All patients  
(N=1212) 
No prior PCI  
(N=1056) 
Prior PCI  
(N=156) p-value 
Surgical characteristics in those randomized to and 
received surgery  
N=555 N=485 N=70  
Number of conduits    0.399 
1 69 (12.4%) 63 (13.0%) 6 (8.6%)  
2 175 (31.5%) 148 (30.5%) 27 (38.6%)  
3 236 (42.5%) 206 (42.5%) 30 (42.9%)  
>3 75 (13.5%) 68 (14.0%) 7 (10.0%)  
Number of arterial conduits    0.819 
0 50 (9.0%) 44 (9.1%) 6 (8.6%)  
1 446 (80.4%) 388 (80.0%) 58 (82.9%)  
>1 59 (10.6%) 53 (10.9%) 6 (8.6%)  
Number of distal anastomoses    0.312 
0 7 (1.3%) 5 (1.0%) 2 (2.9%)  
1 63 (11.4%) 57 (11.8%) 6 (8.7%)  
2 128 (23.1%) 109 (22.5%) 19 (27.5%)  
3 221 (39.9%) 192 (39.6%) 29 (42.0%)  
4 98 (17.7%) 91 (18.8%) 7 (10.1%)  
>4 37 (6.7%) 31 (6.4%) 6 (8.7%)  
 
LVEF=left ventricular ejection fraction; ESVI=end systolic volume index; ICD=internal cardiac defibrillator;  
CABG=coronary artery bypass graft; CCS=Canadian Cardiovascular Society;  NYHA=New York Heart 
Association; ACE=angiotensin converting enzyme;  ARB=angiotensin receptor blocker; LAD=left anterior 
descending artery.
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Table 2. Association between prior PCI and outcomes* 
 
Total events  
(KM rate at 10 years) Unadjusted Adjusted** 
Outcome 
 
No prior PCI 
(n=1056) 
Prior PCI 
(n=156) 
HR (95% CI) for 
prior PCI p-value 
HR (95% CI) for 
prior PCI p-value 
All-cause mortality 649 (64.3%) 91 (60.2%) 0.88 (0.71, 1.10) 0.261 0.92 (0.74, 1.15) 0.475 
Cardiovascular mortality 478 (51.0%) 60 (44.5%) 0.79 (0.60, 1.03) 0.080 0.85 (0.64, 1.11) 0.235 
All-cause mortality or CV 
hospitalization 
850 (83.5%) 135 (89.1%) 1.20 (1.00, 1.44) 0.050 1.19 (0.99, 1.44) 0.065 
CV hospitalization 514 (64.1%) 104 (80.0%) 1.51 (1.22, 1.87) <0.001 1.43 (1.15, 1.77) 0.001 
 
*Intention to treat analyses 
**Models are adjusted for baseline age, sex, region, creatinine clearance, randomized treatment, prior  
CABG, diseased vessels, heart rate, NYHA class, AF, MR, ESVI, diabetes, stroke, current smoking,  
chronic renal insufficiency, depression, and ACE/ARB u
Table 3. Treatment as received effects by history of PCI 
 No Prior PCI Prior PCI   
Outcome MED CABG 
Unadjusted HR 
(95% CI) 
Adjusted
*
 HR 
(95% CI) MED CABG 
Unadjusted 
HR (95% CI) 
Adjusted
*
 HR 
(95% CI) 
Unadjusted 
interaction 
p-value 
Adjusted
*
 
interaction 
p-value 
All-cause mortality 350 
(70.1%) 
314 
(58.7%) 
0.76 (0.65, 
0.88) 
0.75 (0.64, 
0.88) 
52 
(67.1%) 
41 
(53.3%) 
0.65 (0.43, 
0.98) 
0.63 (0.41, 
0.95) 
0.500 0.414 
Cardiovascular 
mortality 
270 
(59.2%) 
214 
(43.1%) 
0.68 (0.57, 
0.82) 
0.67 (0.56, 
0.81) 
36 
(52.5%) 
24 
(36.2%) 
0.57 (0.34, 
0.95) 
0.58 (0.34, 
0.97) 
0.502 0.581 
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 No Prior PCI Prior PCI   
Outcome MED CABG 
Unadjusted HR 
(95% CI) 
Adjusted
*
 HR 
(95% CI) MED CABG 
Unadjusted 
HR (95% CI) 
Adjusted
*
 HR 
(95% CI) 
Unadjusted 
interaction 
p-value 
Adjusted
*
 
interaction 
p-value 
All-cause mortality or 
CV hospitalization 
439 
(87.6%) 
417 
(79.6%) 
0.80 (0.70, 
0.92) 
0.81 (0.70, 
0.93) 
73 
(100%) 
62 
(80.5%) 
0.64 (0.45, 
0.89) 
0.67 (0.47, 
0.94) 
0.211 0.305 
CV hospitalization 263 
(67.6%) 
254 
(61.1%) 
0.83 (0.70, 
0.99) 
0.86 (0.72, 
1.02) 
56 
(100%) 
48 
(69.8%) 
0.66 (0.45, 
0.97) 
0.72 (0.48, 
1.06) 
0.283 0.413 
 
       *Models are adjusted for baseline age, sex, region, creatinine clearance, prior CABG, diseased vessels, heart rate, NYHA class,   
       AF, MR, ESVI, diabetes, stroke, current smoking, chronic renal insufficiency, depression, and ACE/ARB use. 
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Figure 1. Randomized treatment effects by history of PCI 
 
 
 
 
*Models are adjusted for baseline age, sex, region, creatinine clearance, prior CABG, diseased 
vessels, heart rate, NYHA class, AF, MR, ESVI, diabetes, stroke, current smoking, chronic renal 
insufficiency, depression, and ACE/ARB use.  CV=cardiovascular; ACM=all-cause mortality 
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Highlights  
 
 
 Prior reports suggested an association of prior PCI with worse outcomes 
after CABG  
 Patients with severe LV dysfunction were under-represented in those 
studies 
 STICH trial demonstrated survival benefit with CABG in severe LV 
dysfunction  
 This benefit was consistent regardless of the presence of prior PCI  
 Prior PCI should not contra-indicate CABG in patients with LV dysfunction   
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